WO2010126168A3 - Préparation solide - Google Patents

Préparation solide Download PDF

Info

Publication number
WO2010126168A3
WO2010126168A3 PCT/JP2010/057923 JP2010057923W WO2010126168A3 WO 2010126168 A3 WO2010126168 A3 WO 2010126168A3 JP 2010057923 W JP2010057923 W JP 2010057923W WO 2010126168 A3 WO2010126168 A3 WO 2010126168A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid preparation
superior
symbol
iii
salt
Prior art date
Application number
PCT/JP2010/057923
Other languages
English (en)
Other versions
WO2010126168A2 (fr
Inventor
Wataru Hoshina
Makoto Fukuta
Shigeyuki Marunaka
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43032637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010126168(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2010242308A priority Critical patent/AU2010242308A1/en
Priority to CA2760073A priority patent/CA2760073A1/fr
Priority to NZ596395A priority patent/NZ596395A/xx
Priority to EP10719654A priority patent/EP2424501A2/fr
Priority to KR1020117027421A priority patent/KR101797776B1/ko
Priority to JP2011545129A priority patent/JP5666471B2/ja
Priority to MX2011011011A priority patent/MX2011011011A/es
Priority to BRPI1014388A priority patent/BRPI1014388A2/pt
Priority to MA34358A priority patent/MA33280B1/fr
Priority to SG2011078391A priority patent/SG175794A1/en
Priority to CN2010800289702A priority patent/CN102481248B/zh
Priority to EA201171329A priority patent/EA201171329A1/ru
Priority to US13/138,950 priority patent/US20120115837A1/en
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of WO2010126168A2 publication Critical patent/WO2010126168A2/fr
Publication of WO2010126168A3 publication Critical patent/WO2010126168A3/fr
Priority to TNP2011000538A priority patent/TN2011000538A1/en
Priority to IL215962A priority patent/IL215962A0/en
Priority to ZA2011/08375A priority patent/ZA201108375B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention a pour objet une préparation solide comprenant (i) un composé représenté par la formule (I), chaque symbole étant tel que défini dans la description, ou un sel de celui-ci, (ii) un alcool de sucre, et (iii) un antagoniste du calcium, qui est supérieur du point de vue de la propriété de dissolution et de la stabilité.
PCT/JP2010/057923 2009-04-30 2010-04-28 Préparation solide WO2010126168A2 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CA2760073A CA2760073A1 (fr) 2009-04-30 2010-04-28 Preparation solide
SG2011078391A SG175794A1 (en) 2009-04-30 2010-04-28 Solid preparation
MA34358A MA33280B1 (fr) 2009-04-30 2010-04-28 Preparation solide
EP10719654A EP2424501A2 (fr) 2009-04-30 2010-04-28 Préparation solide
KR1020117027421A KR101797776B1 (ko) 2009-04-30 2010-04-28 고형 제제
JP2011545129A JP5666471B2 (ja) 2009-04-30 2010-04-28 固形製剤
MX2011011011A MX2011011011A (es) 2009-04-30 2010-04-28 Preparacion solida.
BRPI1014388A BRPI1014388A2 (pt) 2009-04-30 2010-04-28 preparação de sólido.
NZ596395A NZ596395A (en) 2009-04-30 2010-04-28 Stable solid benzimidazole derivative preparation having optimized dissolution property
AU2010242308A AU2010242308A1 (en) 2009-04-30 2010-04-28 Solid preparation
EA201171329A EA201171329A1 (ru) 2009-04-30 2010-04-28 Твердый препарат
CN2010800289702A CN102481248B (zh) 2009-04-30 2010-04-28 固体制剂
US13/138,950 US20120115837A1 (en) 2009-04-30 2010-04-28 Solid Preparation
TNP2011000538A TN2011000538A1 (en) 2009-04-30 2011-10-24 Solid preparation
IL215962A IL215962A0 (en) 2009-04-30 2011-10-26 Soilid preparation
ZA2011/08375A ZA201108375B (en) 2009-04-30 2011-11-15 Solid preparation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2009-111381 2009-04-30
JP2009111381 2009-04-30
JP2010068625 2010-03-24
JP2010-068625 2010-03-24

Publications (2)

Publication Number Publication Date
WO2010126168A2 WO2010126168A2 (fr) 2010-11-04
WO2010126168A3 true WO2010126168A3 (fr) 2011-03-03

Family

ID=43032637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/057923 WO2010126168A2 (fr) 2009-04-30 2010-04-28 Préparation solide

Country Status (24)

Country Link
EP (1) EP2424501A2 (fr)
JP (1) JP5666471B2 (fr)
KR (1) KR101797776B1 (fr)
CN (1) CN102481248B (fr)
AU (1) AU2010242308A1 (fr)
BR (1) BRPI1014388A2 (fr)
CA (1) CA2760073A1 (fr)
CL (1) CL2011002662A1 (fr)
CO (1) CO6470841A2 (fr)
CR (1) CR20110581A (fr)
DO (1) DOP2011000329A (fr)
EA (1) EA201171329A1 (fr)
EC (1) ECSP11011494A (fr)
GE (1) GEP20135940B (fr)
IL (1) IL215962A0 (fr)
MA (1) MA33280B1 (fr)
MX (1) MX2011011011A (fr)
MY (1) MY158158A (fr)
NZ (1) NZ596395A (fr)
PE (1) PE20120315A1 (fr)
SG (1) SG175794A1 (fr)
TW (1) TWI438201B (fr)
WO (1) WO2010126168A2 (fr)
ZA (1) ZA201108375B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
KR101535586B1 (ko) * 2014-08-01 2015-07-09 에스케이케미칼주식회사 무정형 또는 열역학적 준 안정형 리바록사반을 포함하는 약학 제제
KR101806004B1 (ko) * 2015-01-30 2017-12-08 씨제이헬스케어 주식회사 칸데사르탄 및 암로디핀을 포함하는 약제학적 조성물
CN106668016B (zh) * 2015-11-11 2020-06-23 江苏先声药业有限公司 阿齐沙坦和苯磺酸氨氯地平组合物的固体制剂及其制备方法
JP2017210435A (ja) * 2016-05-25 2017-11-30 ダイト株式会社 イルベサルタン及びアムロジピンベシル酸塩配合錠の製造方法
JP2019001782A (ja) * 2017-06-14 2019-01-10 東和薬品株式会社 二層錠
JP7101464B2 (ja) * 2017-09-28 2022-07-15 エルメッド株式会社 アジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤の品質向上方法、並びにアジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤及びその製造方法
CN108210472A (zh) * 2017-12-15 2018-06-29 蚌埠丰原医药科技发展有限公司 一种西尼地平固体分散体片剂及其制备方法
CN108685925B (zh) * 2018-05-15 2019-12-06 徐州医科大学 一种化合物AB-38b在制备治疗糖尿病肾病药物方面的应用
JP2020075869A (ja) * 2018-11-05 2020-05-21 日本ケミファ株式会社 カルシウム拮抗剤及びアンジオテンシンｉｉ受容体拮抗剤を有効成分として含有する錠剤
JP2020090471A (ja) * 2018-12-07 2020-06-11 ニプロ株式会社 アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
JP7206872B2 (ja) * 2018-12-07 2023-01-18 ニプロ株式会社 アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
JP7441105B2 (ja) * 2020-03-31 2024-02-29 日本ジェネリック株式会社 アジルサルタン及びアムロジピンベシル酸塩を含有するフィルムコーティング錠

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0753301A1 (fr) * 1993-06-07 1997-01-15 Takeda Chemical Industries, Ltd. Combinaison de benzimidazoles ayant une activité antagoniste de l'angiotensine-II avec des diurétiques
EP1369130A1 (fr) * 2001-03-16 2003-12-10 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
EP1452176A1 (fr) * 2001-12-03 2004-09-01 Takeda Chemical Industries, Ltd. Agents pour ameliorer l'etat de resistance de l'insuline
WO2007001066A1 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Préparation pharmaceutique contenant un antagoniste du récepteur de l'angiotensine ii et un bloqueur du canal calcique
WO2010035806A1 (fr) * 2008-09-25 2010-04-01 武田薬品工業株式会社 Composition pharmaceutique solide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2814513B2 (ja) * 1988-02-03 1998-10-22 吉富製薬株式会社 溶出性の改良された製剤組成物
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
WO2002006234A1 (fr) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Derives de sulfonate, procede de production et utilisation de ces derives
AU2003235395A1 (en) * 2002-05-22 2003-12-02 Shionogi And Co., Ltd. Pharmaceutical preparation improved in dissolving property of drug slightly soluble in water
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JP2006321726A (ja) * 2005-05-17 2006-11-30 Sysmex Corp 錠剤の溶出性調整方法
JP5063370B2 (ja) * 2005-06-27 2012-10-31 第一三共株式会社 湿式造粒製薬の調製方法
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
CN101652139A (zh) * 2007-03-29 2010-02-17 第一三共株式会社 药物组合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0753301A1 (fr) * 1993-06-07 1997-01-15 Takeda Chemical Industries, Ltd. Combinaison de benzimidazoles ayant une activité antagoniste de l'angiotensine-II avec des diurétiques
EP1844774A2 (fr) * 1993-06-07 2007-10-17 Takeda Pharmaceutical Company Limited Composition pharmaceutique pour le traitement de maladies liées à l'angiotensine II
EP1369130A1 (fr) * 2001-03-16 2003-12-10 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
EP1452176A1 (fr) * 2001-12-03 2004-09-01 Takeda Chemical Industries, Ltd. Agents pour ameliorer l'etat de resistance de l'insuline
WO2007001066A1 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Préparation pharmaceutique contenant un antagoniste du récepteur de l'angiotensine ii et un bloqueur du canal calcique
WO2010035806A1 (fr) * 2008-09-25 2010-04-01 武田薬品工業株式会社 Composition pharmaceutique solide

Also Published As

Publication number Publication date
BRPI1014388A2 (pt) 2016-04-05
SG175794A1 (en) 2011-12-29
CN102481248B (zh) 2013-12-11
CA2760073A1 (fr) 2010-11-04
CL2011002662A1 (es) 2012-06-15
ZA201108375B (en) 2013-01-30
EP2424501A2 (fr) 2012-03-07
AU2010242308A1 (en) 2011-12-01
WO2010126168A2 (fr) 2010-11-04
TW201041873A (en) 2010-12-01
DOP2011000329A (es) 2011-11-15
GEP20135940B (en) 2013-10-10
KR20120026060A (ko) 2012-03-16
IL215962A0 (en) 2012-01-31
KR101797776B1 (ko) 2017-11-14
JP2012525323A (ja) 2012-10-22
MX2011011011A (es) 2011-11-02
CN102481248A (zh) 2012-05-30
CR20110581A (es) 2012-01-19
ECSP11011494A (es) 2011-12-30
TWI438201B (zh) 2014-05-21
MA33280B1 (fr) 2012-05-02
CO6470841A2 (es) 2012-06-29
MY158158A (en) 2016-09-15
EA201171329A1 (ru) 2012-05-30
PE20120315A1 (es) 2012-04-07
JP5666471B2 (ja) 2015-02-12
NZ596395A (en) 2013-06-28

Similar Documents

Publication Publication Date Title
WO2010126168A3 (fr) Préparation solide
HUS2000039I1 (hu) 4-Amino-3,6-diklórpiridin-2-karbonsavat tartalmazó herbicid készítmények
WO2009030469A8 (fr) Nouveaux fongicides
IL219866A0 (en) Salt form of a multi-arm polymer-drug conjugate, compositions comprising the same, methods of producing the same and uses thereof
WO2009057079A3 (fr) Nouveaux dérivés de pyrimidine
WO2010063700A8 (fr) Nouveaux microbiocides
WO2011012816A3 (fr) Formulation pharmaceutique
WO2010030598A3 (fr) Formulations pharmaceutiques comprenant du pemetrexed
WO2010118866A8 (fr) Composition contenant du trehalulose, sa preparation et son utilisation
WO2011077043A3 (fr) Derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
WO2007133562A3 (fr) Composés d'hétéroaryle monocyclique
WO2010015657A3 (fr) Nouveaux alcoxypyrazoles
WO2011009938A3 (fr) Stambomycine et dérivés, leur production et leur utilisation comme médicaments
BRPI0912099A2 (pt) preparação percutaneamente absorvível
WO2009127718A3 (fr) Nouveaux microbiocides
WO2008073863A3 (fr) Préparation et utilité d'allylamines substituées
WO2009156724A3 (fr) Nouveaux composés
WO2010013835A3 (fr) Composition pharmaceutique solide
WO2010039885A3 (fr) Formes cristallines du dexlansoprazole
PL2454358T3 (pl) Stały, zapach przekazujący zestaw o dobrej rozpuszczalności w zimnej wodzie
WO2011047530A8 (fr) Dérivés de caroténoïde, procédé de préparation et utilisation de ceux-ci
WO2009152474A3 (fr) Procédé de préparation de dérivés de (3s)-3-amino-n-cyclopropyl-2-hydroxyalcanamide
HK1144192A1 (en) Stable crystalline salt of (r)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester (r)-3--345- 1-[222]
WO2010136105A3 (fr) Carboxylates d'ammonium
CL2008000598A1 (es) Procedimiento de preparacion de 3-metil-4-fenilisoxazolo [3,4-d]piridazin-7(6h)-ona.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080028970.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10719654

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/011011

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2011545129

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2011002662

Country of ref document: CL

Ref document number: 2760073

Country of ref document: CA

Ref document number: 215962

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 0143211

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 001882-2011

Country of ref document: PE

Ref document number: 2010719654

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: CR2011-000581

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2010242308

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 596395

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 8945/DELNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20117027421

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201171329

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 12480

Country of ref document: GE

Ref document number: 11164599

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2010242308

Country of ref document: AU

Date of ref document: 20100428

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13138950

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1014388

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1014388

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20111028